DBP: A Drug Target / Disease Biomarker (G1628)

Target Name: DBP

NCBI ID: G1628

Content of Review Report on DBP Target / Biomarker

DBP

DBP: A Drug Target / Disease Biomarker

DBP-1 (doublecortin) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a 26 kDa glycoprotein that consists of two transmembrane regions and a cytoplasmic tail. DBP-1 has been identified as a potential drug target and has been shown to play a role in various biological processes, including cell signaling, inflammation, and neurodegeneration.

The research on DBP-1 began in the 1990s, when scientists identified it as a protein that was expressed in the brain and was involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Since then, more research has been conducted on DBP-1, and it has been shown to be involved in a wide range of biological processes, including:

1. Cell signaling: DBP-1 has been shown to play a role in cell signaling, particularly in the regulation of intracellular signaling pathways. It has been shown to interact with various signaling molecules, including TGF-β1, NF-kappa-B, and PI3K.
2. Inflammation: DBP-1 has been shown to be involved in the regulation of inflammation, both in the brain and in other tissues. It has been shown to interact with various cytokines and to play a role in the recruitment of immune cells to the site of inflammation.
3. Neurodegeneration: DBP-1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has been shown to interact with various proteins involved in neurodegeneration, including tau, beta-amyloid, and neurofilament.
4. Pain perception: DBP-1 has been shown to play a role in pain perception, both in the brain and in other tissues. It has been shown to interact with various pain receptors and to play a role in the regulation of pain signaling.

In addition to its role in biology, DBP-1 has also been shown to be a potential drug target. Several studies have shown that inhibiting DBP-1 can protect against neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, DBP-1 has been shown to be involved in various signaling pathways, making it a potential target for small molecules that can modulate these pathways.

One of the most promising strategies for targeting DBP-1 is the use of small molecules that can modulate its activity. Several studies have shown that compounds that can inhibit DBP-1 function can protect against neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These compounds have been shown to modulate various signaling pathways, including cell signaling, inflammation, and neurodegeneration.

For example, one class of compounds that can inhibit DBP-1 function is called SPT (small- molecule TRK inhibitors). These compounds are commonly used to treat hypertension and have been shown to be effective in protecting against neurodegenerative diseases. SPT inhibitors work by binding to TRK, a protein that is involved in cell signaling, and by inhibiting its activity, they can modulate the activity of DBP-1.

Another class of compounds that can inhibit DBP-1 function is called URL inhibitors. These compounds are commonly used to treat diabetes and have been shown to be effective in protecting against neurodegenerative diseases. URL inhibitors work by binding to a protein called URIC, which is involved in the regulation of inflammation. By inhibiting URIC activity, they can modulate the activity of DBP-1 and protect against neurodegenerative diseases.

In conclusion, DBP-1 is a protein that is involved in a wide range of biological processes and has been shown to play a role in the development and progression of neurodegenerative diseases. It is a potential drug target and has been shown to interact with various signaling molecules, including TGF-β1, NF-kappa-B, and PI3K. Additionally, DBP-1 has also been shown to be involved in cell signaling, inflammation, and neurodegeneration, making it a

Protein Name: D-box Binding PAR BZIP Transcription Factor

Functions: This transcriptional activator recognizes and binds to the sequence 5'-RTTAYGTAAY-3' found in the promoter of genes such as albumin, CYP2A4 and CYP2A5. It is not essential for circadian rhythm generation, but modulates important clock output genes. May be a direct target for regulation by the circadian pacemaker component clock. May affect circadian period and sleep regulation

The "DBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets